203 related articles for article (PubMed ID: 34436668)
1. Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience.
Welland S; deCastro T; Bathon M; Wirth TC; Reineke-Plaaß T; Saborowski M; Lehmann U; Saborowski A; Vogel A
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2137-2144. PubMed ID: 34436668
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets in GI malignancies - A pathologist's perspective.
Pawar S; Sharma A
Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S43-S51. PubMed ID: 34135137
[TBL] [Abstract][Full Text] [Related]
3. Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.
Keller RB; Mazor T; Sholl L; Aguirre AJ; Singh H; Sethi N; Bass A; Nagaraja AK; Brais LK; Hill E; Hennessey C; Cusick M; Del Vecchio Fitz C; Zwiesler Z; Siegel E; Ovalle A; Trukhanov P; Hansel J; Shapiro GI; Abrams TA; Biller LH; Chan JA; Cleary JM; Corsello SM; Enzinger AC; Enzinger PC; Mayer RJ; McCleary NJ; Meyerhardt JA; Ng K; Patel AK; Perez KJ; Rahma OE; Rubinson DA; Wisch JS; Yurgelun MB; Hassett MJ; MacConaill L; Schrag D; Cerami E; Wolpin BM; Nowak JA; Giannakis M
JCO Precis Oncol; 2023 Jan; 7():e2200342. PubMed ID: 36634297
[TBL] [Abstract][Full Text] [Related]
4. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
5. SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors.
Nakamura Y; Fujisawa T; Taniguchi H; Bando H; Okamoto W; Tsuchihara K; Yoshino T; Ohtsu A
Cancer Sci; 2021 Nov; 112(11):4425-4432. PubMed ID: 34510657
[TBL] [Abstract][Full Text] [Related]
6. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
[TBL] [Abstract][Full Text] [Related]
7. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
Martin-Romano P; Mezquita L; Hollebecque A; Lacroix L; Rouleau E; Gazzah A; Bahleda R; Planchard D; Varga A; Baldini C; Postel-Vinay S; Friboulet L; Loriot Y; Verlingue L; Geraud A; Camus MN; Nicotra C; Soria JC; André F; Besse B; Massard C; Italiano A
JCO Precis Oncol; 2022 Oct; 6():e2100484. PubMed ID: 36315916
[TBL] [Abstract][Full Text] [Related]
8. [Personalized tumor therapy for gastrointestinal tumors].
Ettrich TJ; Perkhofer L; Seufferlein T
Internist (Berl); 2015 Sep; 56(9):1069-78. PubMed ID: 26148698
[TBL] [Abstract][Full Text] [Related]
9. Precision Medicine in Gastrointestinal Pathology.
Wang DH; Park JY
Arch Pathol Lab Med; 2016 May; 140(5):449-60. PubMed ID: 27128302
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
[TBL] [Abstract][Full Text] [Related]
11. Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies.
Dhir M; Choudry HA; Holtzman MP; Pingpank JF; Ahrendt SA; Zureikat AH; Hogg ME; Bartlett DL; Zeh HJ; Singhi AD; Bahary N
Cancer Med; 2017 Jan; 6(1):195-206. PubMed ID: 28028924
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona.
Baraniskin A; Van Laethem JL; Wyrwicz L; Guller U; Wasan HS; Matysiak-Budnik T; Gruenberger T; Ducreux M; Carneiro F; Van Cutsem E; Seufferlein T; Schmiegel W
Eur J Cancer; 2017 Nov; 86():305-317. PubMed ID: 29065378
[TBL] [Abstract][Full Text] [Related]
13. Special Series: Advances in GI Cancer.
Meyerhardt JA; Tepper JE; Venook AP
J Clin Oncol; 2015 Jun; 33(16):1717-20. PubMed ID: 25918284
[No Abstract] [Full Text] [Related]
14. Reimbursement in the Context of Precision Oncology Approaches in Metastatic Breast Cancer: Challenges and Experiences.
Pixberg C; Schulze M; Buschhorn L; Suppelna JP; Mock A; Hlevnjak M; Heublein S; Schumacher-Wulf E; Schneeweiss A
Breast Care (Basel); 2024 Feb; 19(1):10-17. PubMed ID: 38384493
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
16. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.
Colomer R; Miranda J; Romero-Laorden N; Hornedo J; González-Cortijo L; Mouron S; Bueno MJ; Mondéjar R; Quintela-Fandino M
EClinicalMedicine; 2023 Jun; 60():102029. PubMed ID: 37304496
[TBL] [Abstract][Full Text] [Related]
17. Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
Repetto M; Crimini E; Boscolo Bielo L; Guerini-Rocco E; Ascione L; Bonfanti A; Zanzottera C; Mazzarella L; Ranghiero A; Belli C; Criscitiello C; Esposito A; Barberis MCP; Curigliano G
Eur J Cancer; 2023 Apr; 183():79-89. PubMed ID: 36801623
[TBL] [Abstract][Full Text] [Related]
18. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
19. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
[TBL] [Abstract][Full Text] [Related]
20. Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
Judd S; Revon-Riviere G; Grover SA; Deyell RJ; Vanan MI; Lewis VA; Pecheux L; Zorzi AP; Goudie C; Santiago R; Tran TH; Abbott LS; Brossard J; Moorehead P; Alvi S; Portwine C; Denburg A; Whitlock JA; Cohen-Gogo S; Morgenstern DA
Cancer Med; 2024 Feb; 13(3):e7033. PubMed ID: 38400668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
